Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

Stopped Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.

Conditions

• Triple Negative Breast Cancer

Interventions

• DRUG: Ociperlimab
• DRUG: Tislelizumab
• DRUG: Paclitaxel
• DRUG: Nab-paclitaxel
• DRUG: Carboplatin
• DRUG: Placebo
• DRUG: Pembrolizumab
• DRUG: Gemcitabine

Sponsor

Novartis Pharmaceuticals